262 related articles for article (PubMed ID: 33917882)
1. Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities.
Arias-Pinilla GA; Modjtahedi H
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33917882
[TBL] [Abstract][Full Text] [Related]
2. Development of novel monoclonal antibodies against CD109 overexpressed in human pancreatic cancer.
Arias-Pinilla GA; Dalgleish AG; Mudan S; Bagwan I; Walker AJ; Modjtahedi H
Oncotarget; 2018 Apr; 9(28):19994-20007. PubMed ID: 29731998
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic application of monoclonal antibodies in cancer: advances and challenges.
Modjtahedi H; Ali S; Essapen S
Br Med Bull; 2012; 104():41-59. PubMed ID: 23118261
[TBL] [Abstract][Full Text] [Related]
4. Development and application of two novel monoclonal antibodies against overexpressed CD26 and integrin α3 in human pancreatic cancer.
Arias-Pinilla GA; Dalgleish AG; Mudan S; Bagwan I; Walker AJ; Modjtahedi H
Sci Rep; 2020 Jan; 10(1):537. PubMed ID: 31953437
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal Antibodies: A Review.
Singh S; Kumar NK; Dwiwedi P; Charan J; Kaur R; Sidhu P; Chugh VK
Curr Clin Pharmacol; 2018; 13(2):85-99. PubMed ID: 28799485
[TBL] [Abstract][Full Text] [Related]
6. New monoclonal antibodies in renal transplantation.
Vincenti F
Minerva Urol Nefrol; 2003 Mar; 55(1):57-66. PubMed ID: 12773967
[TBL] [Abstract][Full Text] [Related]
7. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
8. Omalizumab: anti-IgE monoclonal antibody E25, E25, humanised anti-IgE MAb, IGE 025, monoclonal antibody E25, Olizumab, Xolair, rhuMAb-E25.
BioDrugs; 2002; 16(5):380-6. PubMed ID: 12408744
[TBL] [Abstract][Full Text] [Related]
9. Mechanistic considerations for the use of monoclonal antibodies for cancer therapy.
Glassman PM; Balthasar JP
Cancer Biol Med; 2014 Mar; 11(1):20-33. PubMed ID: 24738036
[TBL] [Abstract][Full Text] [Related]
10. Emerging antibodies for the treatment of pancreatic cancer.
Andrikou K; Peterle C; Pipitone S; Salati M; Cascinu S
Expert Opin Emerg Drugs; 2017 Mar; 22(1):39-51. PubMed ID: 28253833
[TBL] [Abstract][Full Text] [Related]
11. Specificity delivers: therapeutic role of tumor antigen-specific antibodies in pancreatic cancer.
Jhaveri DT; Zheng L; Jaffee EM
Semin Oncol; 2014 Oct; 41(5):559-75. PubMed ID: 25440603
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibodies as therapeutics in human malignancies.
Pandey M; Mahadevan D
Future Oncol; 2014 Mar; 10(4):609-36. PubMed ID: 24754592
[TBL] [Abstract][Full Text] [Related]
13. Single-chain antibodies in pancreatic cancer.
Colcher D; Pavlinkova G; Beresford G; Booth BJ; Batra SK
Ann N Y Acad Sci; 1999 Jun; 880():263-80. PubMed ID: 10415872
[TBL] [Abstract][Full Text] [Related]
14. Immune- and Non-Immune-Mediated Adverse Effects of Monoclonal Antibody Therapy: A Survey of 110 Approved Antibodies.
Baldo BA
Antibodies (Basel); 2022 Feb; 11(1):. PubMed ID: 35323191
[TBL] [Abstract][Full Text] [Related]
15. Novel immune check point inhibiting antibodies in cancer therapy-Opportunities and challenges.
Diesendruck Y; Benhar I
Drug Resist Updat; 2017 Jan; 30():39-47. PubMed ID: 28363334
[TBL] [Abstract][Full Text] [Related]
16. Licensed monoclonal antibodies and associated challenges.
Khan AH; Sadroddiny E
Hum Antibodies; 2015 Dec; 23(3-4):63-72. PubMed ID: 27472864
[TBL] [Abstract][Full Text] [Related]
17. SCNrank: spectral clustering for network-based ranking to reveal potential drug targets and its application in pancreatic ductal adenocarcinoma.
Liu E; Zhang ZZ; Cheng X; Liu X; Cheng L
BMC Med Genomics; 2020 Apr; 13(Suppl 5):50. PubMed ID: 32241274
[TBL] [Abstract][Full Text] [Related]
18. A novel inhibitory anti-invasive MAb isolated using phenotypic screening highlights AnxA6 as a functionally relevant target protein in pancreatic cancer.
O'Sullivan D; Dowling P; Joyce H; McAuley E; McCann A; Henry M; McGovern B; Barham P; Kelleher FC; Murphy J; Kennedy S; Swan N; Moriarty M; Clynes M; Larkin A
Br J Cancer; 2017 Oct; 117(9):1326-1335. PubMed ID: 28881357
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal antibody therapy for prostate cancer.
Jakobovits A
Handb Exp Pharmacol; 2008; (181):237-56. PubMed ID: 18071949
[TBL] [Abstract][Full Text] [Related]
20. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
